中草药

橙皮素与盐酸巴马汀共无定形的制备、表征及体外活性评价

PDF下载

中草药 | 药剂与工艺 2026,57(7): 2536-2545

收起

中草药 |药剂与工艺 2026 , 57 (7) : 2536 -2545

橙皮素与盐酸巴马汀共无定形的制备、表征及体外活性评价

全屏

梁玲¹, 李延广¹, 李闯¹, 陈力丰¹, 张燕杰¹, 娄本勇¹

作者信息

通讯作者:

娄本勇

作者简介:

梁玲: 梁玲(1990-),女,博士,实验师,主要从事中药超分子化学研究。Tel:(0591)83763589 E-mail:liangling@mju.edu.cn

Preparation, characterization and in vitro activity evaluation of hesperetin co-amorphous with palmatine hydrochloride

LIANG Ling, LI Yanguang, LI Chuang, CHEN Lifeng, ZHANG Yanjie, LOU Benyong

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.07.010

文章导航

摘要

收起

目的制备橙皮素与盐酸巴马汀共无定形（hesperetin and palmatine hydrochloride co-amorphous system，Hes-PH CAS），旨在开发橙皮素新固体形态、提高橙皮素溶解度和溶出度。方法采用旋转蒸发法获得Hes-PH CAS，通过粉末X射线衍射仪、差示扫描量热仪、动态水蒸气吸附仪、固体核磁共振波谱仪等仪器分析技术对Hes-PH CAS的固态特性进行表征，并利用高效液相色谱仪考察其溶解度及溶出行为，并进一步通过自由基清除率、细胞增殖抑制率评估其抗氧化活性和抗肿瘤活性。结果 Hes-PH CAS具有单一玻璃化转变温度（glass transition temperature，Tg，104.5 ℃）及分子间氢键作用。该共无定形同时改变了橙皮素和盐酸巴马汀2种药物的溶解度和溶出行为，提高橙皮素的溶解度而降低盐酸巴马汀的溶解度，促进橙皮素的释放而延缓盐酸巴马汀的释放。抗氧化及抗肿瘤实验结果表明，Hes-PH CAS的自由基清除率和HT-29/HCT 116细胞增殖抑制率均高于原料药，而且共无定形中2种药物对自由基清除率、细胞增殖抑制率具有一定的增效作用。结论所制备的Hes-PH CAS提高了橙皮素溶解度和溶出度，2种药物组分展现出更好的抗氧化和抗肿瘤作用。

关键词

橙皮素 / 盐酸巴马汀 / 共无定形 / 溶解度 / 溶出度 / 体外活性 / 抗氧化活性 / 抗肿瘤活性

Abstract

收起

Objective Hesperetin and palmatine hydrochloride co-amorphous system (Hes-PH CAS) was prepared to develop new solid forms and improve the solubility and dissolution of hesperetin. Methods Hes-PH CAS was obtained via the rotary evaporation method. The solid-state characteristics were characterized by powder X-ray diffraction, differential scanning calorimetry, dynamic vapor sorption and solid-state nuclear magnetic resonance, respectively. The solubility and dissolution behavior were investigated by high-performance liquid chromatography. Furthermore, the antioxidant and antitumor activities were analyzed through radical scavenging assay and cell proliferation studies. Results Hes-PH CAS possessed a single glass transition temperature (T_g = 104.5 ℃) and exhibited intermolecular interactions. The co-amorphous simultaneously influenced the solubility and dissolution of both drugs, increasing hesperetin solubility while decreasing palmatine hydrochloride solubility, and promoting hesperetin release while delaying palmatine hydrochloride release. The antioxidant and anti-tumor results demonstrated that the free radical scavenging rate and HT-29/HCT 116 cell inhibition rate of Hes-PH CAS were higher than those of the individual raw materials, indicating a synergistic effect between the two drugs in terms of both free radical scavenging and cell inhibition. Conclusion The prepared Hes-PH CAS improved the solubility and dissolution of hesperetin, with two pharmaceutical components exhibiting good antioxidant and antitumor effects.

Key words

hesperetin / palmatine hydrochloride / co-amorphous / solubility / dissolution / in vitro activity / antioxidant activities / antitumor activities

引用本文

梁玲, 李延广, 李闯, 陈力丰, 张燕杰, 娄本勇. 橙皮素与盐酸巴马汀共无定形的制备、表征及体外活性评价. 中草药, 2026 , 57 (7) : 2536 -2545 . DOI: 10.7501/j.issn.0253-2670.2026.07.010

LIANG Ling, LI Yanguang, LI Chuang, CHEN Lifeng, ZHANG Yanjie, LOU Benyong. Preparation, characterization and in vitro activity evaluation of hesperetin co-amorphous with palmatine hydrochloride[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (7) : 2536 -2545 . DOI: 10.7501/j.issn.0253-2670.2026.07.010

基金

收起

福州市科技计划项目 (2024-SG-009); 闽江学院引进人才预研项目 (MJY23007); 大学生创新训练项目 (202410395034)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Liu Y F, Liang Y S, Jing Y H, et al. Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs[J]. Drug Des Devel Ther, 2024, 18:1469-1495.
Pinal R. Enhancing the bioavailability of poorly soluble drugs[J]. Pharmaceutics, 2024, 16(6):758.
Dengale S J, Grohganz H, Rades T, et al. Recent advances in co-amorphous drug formulations[J]. Adv Drug Deliv Rev, 2016, 100:116-125.
Han J W, Wei Y F, Lu Y, et al. Co-amorphous systems for the delivery of poorly water-soluble drugs:Recent advances and an update[J]. Expert Opin Drug Deliv, 2020,17(10):1411-1435.
Shelke R, Velagacherla V, Nayak U Y. Recent advances in dual-drug co-amorphous systems[J]. Drug Discov Today,2024, 29(2):103863.
Löbmann K, Strachan C, Grohganz H, et al. Coamorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions[J]. Eur J Pharm Biopharm,2012, 81(1):159-169.
Renuka, Singh S K, Gulati M, et al. Stable amorphous binary systems of glipizide and atorvastatin powders with enhanced dissolution profiles:Formulation and characterization[J]. Pharm Dev Technol, 2017, 22(1):13-25.
Löbmann K, Laitinen R, Grohganz H, et al. Coamorphous drug systems:Enhanced physical stability and dissolution rate of indomethacin and naproxen[J]. Mol Pharm, 2011,8(5):1919-1928.
Moinuddin S M, Ruan S D, Huang Y T, et al. Facile formation of co-amorphous atenolol and hydrochlorothiazide mixtures via cryogenic-milling:Enhanced physical stability, dissolution and pharmacokinetic profile[J]. Int J Pharm, 2017, 532(1):393-400.
Yang H L, Chen S C, Senthil Kumar K J, et al. Antioxidant and anti-inflammatory potential of hesperetin metabolites obtained from hesperetin-administered rat serum:An ex vivo approach[J]. J Agric Food Chem, 2012, 60(1):522-532.
Wang R, Li W H, Fang C, et al. Extraction and identification of new flavonoid compounds in dandelion Taraxacum mongolicum Hand.-Mazz. with evaluation of antioxidant activities[J]. Sci Rep, 2023, 13(1):2166.
Parhiz H, Roohbakhsh A, Soltani F, et al. Antioxidant and anti-inflammatory properties of the Citrus flavonoids hesperidin and hesperetin:An updated review of their molecular mechanisms and experimental models[J].Phytother Res, 2015, 29(3):323-331.
Roohbakhsh A, Parhiz H, Soltani F, et al. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases[J]. Life Sci, 2015, 124:64-74.
Ferreira O, Schröder B, Pinho S P. Solubility of hesperetin in mixed solvents[J]. J Chem Eng Data, 2013, 58(9):2616-2621.
Qiu S L, Deng X Z, Qian K, et al. Study on the structure,solubilities, antibacterial activities and in vivo toxicity of hesperetin and norfloxacin cocrystal[J]. Pharm Chem J,2024, 58(5):765-774.
Liu Y J, Yang F, Zhao X H, et al. Crystal structure,solubility, and pharmacokinetic study on a hesperetin cocrystal with piperine as coformer[J]. Pharmaceutics,2022, 14(1):94.
Wang J, Dai X L, Lu T B, et al. Temozolomide-hesperetin drug-drug cocrystal with optimized performance in stability, dissolution, and tabletability[J]. Cryst Growth Des, 2021, 21(2):838-846.
Zhang Y J, Li Y G, Liu L, et al. Two cocrystal polymorphs of palmatine chloride with racemic hesperetin[J]. Cryst Growth Des, 2022, 22(2):1073-1082.
Zhang G G Z, Law D, Schmitt E A, et al. Phase transformation considerations during process development and manufacture of solid oral dosage forms[J]. Adv Drug Deliv Rev, 2004, 56(3):371-390.
Knapik-Kowalczuk J, Chmiel K, Jurkiewicz K, et al.Physical stability and viscoelastic properties of coamorphous ezetimibe/simvastatin system[J].Pharmaceuticals, 2019, 12(1):40.
Ohta M, Tozuka Y, Oguchi T, et al. Water vapor adsorption properties of amorphous cefditoren pivoxil evaluated by adsorption isotherms and microcalorimetry[J]. Drug Dev Ind Pharm, 2000, 26(6):643-649.
Ueda H, Wu W Q, Löbmann K, et al. Application of a salt coformer in a co-amorphous drug system dramatically enhances the glass transition temperature:A case study of the ternary system carbamazepine, citric acid, and larginine[J]. Mol Pharm, 2018, 15(5):2036-2044.
Thakuria R, Sarma B. Drug-drug and drug-nutraceutical cocrystal/salt as alternative medicine for combination therapy:A crystal engineering approach[J]. Crystals,2018, 8(2):101.
Slika H, Mansour H, Wehbe N, et al. Therapeutic potential of flavonoids in cancer:ROS-mediated mechanisms[J].Biomed Pharmacother, 2022, 146:112442.
Ji Z K, Deng W, Chen D, et al. Recent understanding of the mechanisms of the biological activities of hesperidin and hesperetin and their therapeutic effects on diseases[J].Heliyon, 2024, 10(5):e26862.
Shang X F, Yang C J, Morris-Natschke S L, et al.Biologically active isoquinoline alkaloids covering2014-2018[J]. Med Res Rev, 2020, 40(6):2212-2289.
Qin H X, Wang J, Peng J H, et al. A novel temozolomidemyricetin drug-drug cocrystal:Preparation,characterization, property evaluations[J]. Pharmaceutics,2025, 17(7):906.
Wang X J, Du S Z, Zhang R, et al. Drug-drug cocrystals:Opportunities and challenges[J]. Asian J Pharm Sci, 2021,16(3):307-317.

2026年第57卷第7期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.07.010

接收时间：2025-10-28
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-10-28

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.07.010

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT